GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial
Open Access
- 1 March 2013
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 108 (3), 392-400
- https://doi.org/10.1038/ajg.2012.467
Abstract
OBJECTIVES: METHODS: RESULTS: CONCLUSIONS:Keywords
This publication has 27 references indexed in Scilit:
- Cardiovascular clinical trials in Japan and controversies regarding prospective randomized open-label blinded end-point designHypertension Research, 2009
- Small bowel mucosal injury is reduced in healthy subjects treated with celecoxib compared with ibuprofen plus omeprazole, as assessed by video capsule endoscopyAlimentary Pharmacology & Therapeutics, 2007
- Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinationsGut, 2006
- Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I StudyAmerican Journal Of Medicine, 2006
- Development and validation of the pain treatment satisfaction scale (ptss): a patient satisfaction questionnaire for use in patients with chronic or acute painPain, 2004
- Drug switching patterns among patients taking non‐steroidal anti‐inflammatory drugs: a retrospective cohort study of a general practitioners database in the United KingdomPharmacoepidemiology and Drug Safety, 2001
- Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid ArthritisJAMA, 2000
- Individual Nonsteroidal Antiinflammatory Drugs and Other Risk Factors for Upper Gastrointestinal Bleeding and PerforationEpidemiology, 1997
- Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factorsArchives of Internal Medicine, 1994
- Prospective Randomized Open Blinded End-point (PROBE) Study. A novel design for intervention trialsBlood Pressure, 1992